Cancer gene therapy has great potential for decreasing tumor-induced mortality but has been clinically limited by non-targeted and insufficient gene transfer. We evaluated gene therapy targeting hepatocellular carcinoma (HCC) using the herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system and the tissue inhibitor of metalloproteinase 3 (Timp3) gene. Ultrasound-targeted microbubble destruction (UTMD) targeted gene delivery to the tumor tissue, and the a-fetoprotein promoter targeted HSVtk expression to the HCC cells. Human HepG2 cells transfected with the HSVtk or Timp3 gene demonstrated a reduction in cell viability by 440% compared with the vector control. Cell viability was further inhibited by over 50% with co-transfection of the genes. HepG2 cells were inoculated subcutaneously into athymic mice to induce tumors. UTMD-mediated delivery of HSVtk or Timp3 suppressed tumor growth by 445% and increased survival of tumor-bearing animals (Po0.01 vs vector control). Co-delivery of the genes resulted in a further 30% improvement in tumor suppression and significant extension of animal survival (Po0.01 vs vector control). Targeted gene delivery increased the number of apoptotic cells and decreased the vascular density of the tumors. Targeted co-delivery of the genes synergistically improved the antitumor effects and may provide an effective therapy for HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most deadly cancer worldwide. 1 The most common treatment is surgery, but o15% of patients benefit because of the presence of multifocal tumors and/or the risk of postoperative hepatocellular functional deficiency. [2] [3] [4] In addition, the rate of recurrence is high and therapies such as chemotherapy and radiotherapy have produced unsatisfactory results. [5] [6] [7] Liver transplantation has been performed, but the prognosis remains poor because of frequent tumor recurrence. Therefore, novel therapeutic modalities for HCC are urgently needed.
Gene therapy has been evaluated extensively to induce tumor cell necrosis or prevent cell growth. Suicide and growth-inhibition genes have been identified and effectively demonstrated in vitro. The most widely studied suicide gene is the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir (GCV) system. 8, 9 GCV is a substrate for HSVtk but not mammalian thymidine kinase. HSVtk phosphorylates GCV to GCV monophosphate, which is then converted to GCV triphosphate by endogenous cellular nucleoside kinases. Upon incorporation into cellular DNA during S phase, the GCV triphosphate acts as a DNA chain terminator due to lack of a functional 3 0 OH group and hence triggers apoptosis. 10, 11 To enhance the effective cellular necrosis of liver cancer cells, a human a-fetoprotein (AFP) promoter was selected to drive the suicide gene. This modification makes the gene therapy more specific to HCC. 12, 13 A main contributor to tumor growth, invasion and metastasis is a shift in the expression or activity of the degradative matrix metalloproteinases (MMPs) relative to that of the tissue inhibitors of metalloproteinases (TIMPs). 14 The TIMP family comprises four proteases involved in the maintenance of tissue structure. Tissue inhibitor of metalloproteinase 3 (TIMP3) has a unique role as a tumor suppressor, inhibiting tumor cell invasion and vascularization and demonstrating a potent pro-apoptotic effect on tumor cells. [15] [16] [17] [18] Consequently, inactivation of TIMP3 was found in many human tumors. 19, 20 Although in vivo studies demonstrated that gene therapy is effective to prevent tumor cell growth, the lack of targeted delivery to the tumor tissue not only diminished the therapeutic efficacy but increased side effects in healthy tissue. Ultrasoundtargeted microbubble destruction (UTMD) is a non-invasive, efficient, targeted and safe transfection technique that can deliver plasmids to specific organs and tissues. [21] [22] [23] In the present study, we quantified the inhibition of HCC cell growth induced by transfection with HSVtk, Timp3 or both. We also used an established HCC xenograft mouse model to evaluate the in vivo antitumor effects of targeted gene delivery by UTMD. To enhance the specificity of the suicide gene in killing tumor cells, the AFP promoter was used to control the HSVtk gene, ensuring its specific expression in HCC cells. The UTMD technique used to deliver the HSVtk and Timp3 genes targeted the transfection to the HCC tumor cells by rupturing the plasmid-loaded microbubbles within the tumor tissue.
MATERIALS AND METHODS

Cell culture
The human HCC HepG2 cell line was purchased from the American Type Culture Collection (Manassas, VA, USA) and was cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum in 5% CO 2 at 37 1C.
Plasmids and transfection
The pcDNA3.0-TIMP3 plasmid expresses the murine Timp3 gene under the universal cytomegalovirus promoter. 24 The pHSVtk-IRES2-EGFP plasmid was constructed according to the HSVtk coding sequence in GenBank and co-expresses the HSVtk gene and the enhanced green fluorescent protein (EGFP) gene. The cytomegalovirus promoter was replaced by a 0.3-kb AFP promoter synthesized by PCR. The final expression construct was purified and confirmed by sequencing. The pIRES2-EGFP plasmid was used as the vector control.
HepG2 cells were transfected using PolyJet reagent (SignaGen Lab, Ijamsville, MD, USA) according to the manufacturer's specifications. G418 (Geneticin; Life Technologies, Burlington, ON, Canada) was used for 16 days to select HSVtk-transfected cells. Tumor cells were observed under fluorescence microscopy for confirmation of EGFP þ cells.
Protein levels of transfected genes
HSVtk and TIMP3 protein in transfected cells or excised tumor tissue was evaluated by western blot as described previously. 24 MTT assay A total of 2 Â 10 5 transfected HepG2 cells were plated in a six-well plate and treated with 150 mg ml À 1 GCV for 3 days. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to determine the relative number of viable cells based on the conversion of MTT to formazan. A standard microplate reader determined the optical density at 620 nm. Cell proliferation ¼ (absorbance in vector control group À absorbance in testing group)/absorbance in vector group Â 100%.
Lactate dehydrogenase assay
The lactate dehydrogenase assay was performed to determine relative cell necrosis based on the amount of enzyme released. The conditioned media of HepG2 cells was collected 3 days after transfection (Timp3 group) or after transfection followed by GCV administration (HSVtk and vector control groups). A standard microplate reader determined the optical density at 490 nm.
Microbubble preparation
The cationic microbubble was prepared by the method of thin film hydration as previously reported. 25 The microbubbles have an average diameter of 1.6 ± 0.21 mm and a zeta potential of 36.7 ± 2.4 mV.
Animal model and UTMD gene delivery
The study protocol was approved by the Animal Research Committee of University Health Network. All animal procedures were carried out according to the 'Guide for the Care and Use of Laboratory Animals' (NIH, 1996) . Athymic male mice, 8-to 10-weeks-old, with a body weight of 20±2 g were purchased from the National Cancer Institute (Bethesda, MD, USA). The mice were subcutaneously injected in the right flank with 5 Â 10 6 HepG2 cells. Tumors were observed after 28 days. When the tumors had grown to about 200 mm 3 , the mice were randomized into four groups:
Each plasmid (250 mg kg À 1 ) was separately conjugated with microbubbles, and the solution was infused into the tail vein at 900 ml h À 1 in a total volume of 75 ml. The GE Vivid 7 ultrasound system with the 3MS probe was used to target the tumors with a radiation frequency of 1. 
Tumor volume and animal survival
We used calipers to measure the maximum diameter, a, and minimum diameter, b, of the tumors every 3 days and applied the formula V ¼ ab 2 /2 to calculate tumor volume (in mm 3 ). Five mice in each group were followed for 75 days for observation of survival time.
MMP activity
Tumor tissue (n ¼ 4 for vector, n ¼ 5 for Timp3) was snap-frozen 15 days after UTMD gene transfection. The activities of MMP2 and MMP9 in the tumor tissue were quantified using gelatin zymography as described previously 24 and expressed as intensity units.
Histology and immunohistochemistry
On the day of killing, the tumors were excised. Tumor tissue was fixed in 4% formaldehyde, paraffin embedded and sectioned (5.0 mm). Sections were stained with hematoxylin and eosin for histological analysis. The serial sections were stained with an anti-CD31 antibody (Millipore, Etobicoke, ON, Canada), and blood vessel density was quantified by counting the number of CD31 þ vessels in five fields (200Âequals 0.4 mm 2 ) per slide and calculating the mean (n ¼ 4 per group).
Apoptosis
Terminal transferase dUTP nick-end labeling (TUNEL) was performed on cryosections following HSVtk or Timp3 transfection with an In Situ Cell Death Detection kit (Roche). Apoptotic cell death was determined by counting the number of TUNEL þ nuclei in five fields (400Âequals 0.2 mm 2 ) per slide and calculating the mean (n ¼ 4 per group).
Statistical analysis
Results are expressed as mean±s.d. Analyses were performed using GraphPad Prism (v. 4) with the critical a-level set at Po0.05. Survival was analyzed with Kaplan-Meier survival curves and log-rank statistics. Student's t-test was used to compare differences between two groups. One-or two-way analysis of variance (with Tukey or Bonferroni multiple comparison post-tests to specify differences between groups) was used to compare differences among three or more groups when appropriate.
RESULTS
Construction of the HSVtk plasmid
We constructed a pHSVtk-IRES2-EGFP plasmid that co-expressed HSVtk and EGFP (Figure 1a ). The cytomegalovirus promoter was removed and replaced by a 0.3-kb AFP promoter synthesized by PCR. The HSVtk gene is driven by the AFP promoter, which ensures its specific expression in liver cancer cells. The HSVtk gene was inserted into the cloning site, which was confirmed by XhoI and BamHI restriction enzyme digestion, revealing a 1137-bp fragment not present in the control vector (Figure 1b) . DNA sequencing confirmed insertion of the gene (data not shown).
HSVtk and Timp3 plasmids effectively transfected HCC cells The transfection efficiency was evaluated by counting the number of EGFP þ cells (Figure 1c ). We found that 81±13% of transfected cells were EGFP þ , suggesting that over 80% of HepG2 cells were successfully transfected after selection. We observed HSVtk protein (B36 kDa) expression in HSVtk-transfected cells, but negligible expression in control vector-transfected cells, as determined by western blot (Figure 1d) . Similarly, TIMP3 protein (B24 kDa) was present in Timp3-transfected cells but was significantly lower in the vector control group (Figure 1e ). Figure 2b ). The MTT assay was used to determine cell proliferation relative to the control vector without GCV. The HSVtk þ GCV group had significantly inhibited cell growth compared with all other groups (Po0.01; Figure 2c ). However, an inhibitory effect was also observed in cells transfected with the control vector þ GCV, suggesting that the drug itself had a toxic effect on the tumor cells (Po0.05 vs vector). Similarly, HSVtktransfected cells with no GCV treatment exhibited some growth inhibition (Po0.05 vs vector).
GCV treatment enhanced growth inhibition of
Co-transfection with Timp3 and HSVtk synergistically enhanced HCC cytotoxicity The anti-proliferative and pro-apoptotic activities of TIMP3 on HepG2 cells were investigated in culture (Figure 3a) . Transfection of cells with the Timp3 plasmid produced a cytotoxic effect at 3 days as these cells released more lactate dehydrogenase than cells transfected with the control vector and treated with GCV (Po0.01; Figure 3b ). However, co-transfection with both HSVtk and Timp3 followed by GCV produced a greater cytotoxic effect than either Timp3 or HSVtk alone (Po0.01).
TIMP3 and HSVtk expression and MMP activity in HCC xenograft tumor cells
We used an established HCC xenograft tumor model induced by subcutaneous inoculation of HepG2 cells into nude mice. To assess the potential pro-apoptotic and tumoricidal effects of the genes HSVtk þ GCV in tumor tissue, we used western blotting to examine TIMP3 and HSVtk protein expression in the tumor tissue 2 days after UTMD gene transfection (Figures 4a and b) . The TIMP3 protein levels were significantly higher in the Timp3 and HSVtk þ Timp3 groups than the vector control and HSVtk groups. Similarly, HSVtk protein expression was significantly higher in the HSVtk and HSVtk þ Timp3 gene delivery groups than the vector control and Timp3 groups (Po0.01).
TIMP3 is a known inhibitor of both MMP2 and MMP9. Therefore, to assess the potential biological effect of TIMP3, zymography was used to quantify MMP activity in the tumor tissue 15 days after UTMD gene transfection (Figure 4c ). Both MMP2 and MMP9 activity were significantly lower in the Timp3-transfected group compared with the vector control group (Po0.05), indicating downstream effects of Timp3 gene delivery.
UTMD delivery of Timp3 and HSVtk synergistically increased HCC xenograft tumor cell apoptosis and decreased angiogenesis To assess whether UTMD-mediated Timp3 or HSVtk transfection followed by GCV treatment could increase apoptosis of tumor cells in vivo, we performed TUNEL staining of HCC xenograft tumor sections ( Figure 5a ). As shown in Figure 5b , transfection with Timp3 or HSVtk significantly increased tumor cell apoptosis compared with the vector control (Po0.01). Co-delivering the Timp3 and HSVtk genes in tumor-bearing animals synergistically enhanced the apoptotic effect compared with either Timp3 or HSVtk alone (Po0.01).
To investigate whether UTMD-mediated Timp3 transfection or HSVtk transfection and GCV treatment had any effect on tumor angiogenesis, we stained tissue sections for CD31 to detect blood vessels ( Figure 5c ). As expected, the HSVtk gene did not have a significant effect on angiogenesis. However, as shown in Figure 5d , Timp3 significantly reduced tumor angiogenesis compared with the vector control and HSVtk (Po0.01). Additionally, co-delivery of the genes in tumor-bearing animals also suppressed angiogenesis compared with the vector control and HSVtk (Po0.01).
UTMD delivery of Timp3 and HSVtk synergistically inhibited HCC xenograft tumor growth We investigated the antitumor effects of Timp3 and HSVtk þ GCV in vivo. Disease progression, or tumor response, following UTMD (Figure 6b ). Multiple foci of necrosis were observed in mice receiving both Timp3 and HSVtk genes (Figure 6b ). Timp3 and HSVtk each significantly inhibited tumor growth compared with the vector control, decreasing tumor volume by a factor of 1.9 (Po0.01; Figure 6c ). Co-delivery of these two genes synergistically enhanced the antitumor effect, decreasing tumor volume by a factor of 3.9 (Po0.01 vs vector control). These observations confirm our in vitro results.
UTMD delivery of Timp3 and HSVtk synergistically increased animal survival Tumor-bearing mice from each group were followed for 75 days to assess survival. Survival curves demonstrated that animals receiving UTMD-mediated delivery of the Timp3 or HSVtk gene lived significantly longer compared with animals in the vector control group (Po0.01; Figure 6d ). Co-delivery of both genes resulted in the longest-lived mice (Po0.05).
DISCUSSION
Targeting genes to specific tissues or tumor types is critical to the success of cancer gene therapy. Here we used a tumor-selective promoter to overexpress a cellular necrosis gene in specific human cancer cells. In addition, we used the UTMD technique to target the tumor tissue to specifically enhance targeted gene delivery. The present study reveals the synergistic effect of TIMP3 in killing HCC cells when combined with the HSVtk/GCV suicide gene system. The novelty lies in the fact that Timp3 and HSVtk gene delivery by UTMD synergistically suppressed HCC tumor growth and reduced animal mortality.
Although gene therapy as a treatment for cancer holds great promise, the development of safe and efficient gene delivery techniques is paramount. A barrier to clinical translation of this treatment has been the limited gene delivery. Although viral vector-mediated gene delivery is well characterized and possesses a high transduction efficiency, it can elicit immunogenicity or cytotoxicity, 26, 27 especially when the vector enters the circulation. Gene therapy with plasmids is an acceptable platform for safe gene delivery, but DNA instability and low transfection efficiency have hindered the application of this approach. However, when electrostatically bound to microbubbles, plasmids are protected from degradation in the circulation and can increase transfection when released by UTMD. 28, 29 By modifying the lipid shell, we recently created a cationic microbubble with a high DNA-binding capacity, further enhancing transfection efficiency. 30 Using the UTMD technique, we have previously reported the successful transfer of genes specifically to the rodent heart. 21, 22, 30 UTMD is a non-invasive, efficient and safe gene transfection technique that can target genes to specific tissues. 21, 22 Ultrasound is used to visually detect the microbubbles in the tumor blood vessels after injection into the circulation and then to rupture the microbubbles to deliver the plasmid to the targeted local tissue. Recently, investigation of the UTMD technique has expanded to include its potential utility in the treatment of cancer. In a murine model of squamous cell carcinoma, UTMD delivery of the HSVtk gene resulted in longer tumor doubling time and increased apoptosis. 31 This platform has also been evaluated in hepatoma models. Using a similar human HepG2-induced xenograft tumor model as we report in the current study, Tang et al. delivered the HSVtk gene under both the AFP and KDR promoters. Tumor volume was comparable among all groups, but they demonstrated significantly greater tumor growth inhibition in the treatment groups. Apoptosis was also higher in the treatment groups. However, there was no difference in animal survival. 32 These seemingly ambiguous results may be due in part to the intratumor injection of the microbubbles and plasmids. Previously, another group demonstrated that UTMD-mediated delivery of the HSVtk gene was effective at inhibiting hepatoma tumor growth and increasing animal survival. 23 However, HSVtk expression was not targeted as the gene was not under the control of the AFP promoter, and the tumors were not human in origin but induced by the mouse H22 cell line.
Tumor-selective promoters are potentially important for cancer gene therapy as they permit a cytotoxic agent to be expressed specifically in target cells, minimizing the killing of normal cells. [33] [34] [35] [36] AFP is expressed in the majority of HCC tumors 12, 13 and thus presents a promising approach for targeted gene therapy against HCC. As normal liver cells have a relatively low rate of cell division and very low expression of AFP compared with HCC cells, they are much less sensitive to the DNA synthesis inhibition and killing effect induced by phosphorylated GCV. This reduces unwanted side effects from off-target cell death.
UTMD-mediated gene delivery results in transient transfection, possibly of only a small percentage of the total number of tumor cells. However, the benefit of HSVtk is that transfected cells can exert the bystander effect, in which non-transfected cells are killed in the presence of a minority of cells expressing the suicide gene. Phosphorylated GCV produced by the HSVtk-transfected tumor cells is transferred to neighboring non-transfected cells through gap junctions, amplifying the tumoricidal effect. 37 MMPs and TIMPs are important regulators of cancer growth, invasion and metastasis. TIMP3 has a distinctive role as a tumor suppressor by inhibiting tumor cell growth, invasion, and vascularization and demonstrating a potent pro-apoptotic effect on tumor cells, [15] [16] [17] [18] making it a worthwhile component of anticancer strategies. TIMP3 inhibits MMP2 and MMP9, which contribute to tumor progression. [38] [39] [40] We demonstrated decreased MMP activity in tumor tissue transfected with the Timp3 gene. Timp3 also reduced tumor blood vessel density. These results explain how Timp3 alone significantly increased HCC cell killing in vitro, inhibited tumor growth in vivo and extended the survival of tumor-bearing mice. When Timp3 was combined with the HSVtk/GCV suicide gene system, we observed synergistic cell killing and antitumor effects. This combination was also more effective at extending animal survival than either gene alone.
The data presented here suggest that Timp3 may be used to synergistically enhance HCC tumor suppression when combined with suicide gene delivery. These results are encouraging, although we recognize that our subcutaneous tumor model does 
